{"id":12433,"date":"2026-06-22T05:13:32","date_gmt":"2026-06-22T05:13:32","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=12433"},"modified":"2026-06-22T05:20:35","modified_gmt":"2026-06-22T05:20:35","slug":"alluzience-or-azzalure-picking-the-right-toxin","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/alluzience-or-azzalure-picking-the-right-toxin\/","title":{"rendered":"Alluzience or Azzalure? Picking the Right Toxin"},"content":{"rendered":"\n

A practitioner who has run a fixed Azzalure protocol for years is asked by a patient why the clinic down the road advertises results “within 24 hours.” Both clinics<\/mark><\/a> use a Galderma toxin<\/mark><\/a>. Both quote Speywood units. The difference sits in the vial: one is a powder that has to be reconstituted, the other arrives as a ready-to-use liquid. That single distinction shapes preparation time, dosing accuracy, onset and, increasingly, what patients ask for by name. Understanding where Alluzience<\/mark><\/a> and Azzalure<\/mark><\/a> genuinely differ, and where they are effectively the same drug, makes the choice a clinical one rather than a marketing one.<\/p>\n\n\n\n

The same toxin in two different formats<\/h2>\n\n\n\n

Both products are abobotulinumtoxinA, the same active molecule found in Dysport<\/mark><\/a>, produced by Ipsen and brought to the aesthetic market by Galderma. Both are measured in Speywood units, which are specific to this toxin family and are not interchangeable with the units used by onabotulinumtoxinA (Botox<\/mark><\/a>) or incobotulinumtoxinA (Bocouture<\/mark><\/a>). Fifty Speywood units does not equal fifty Allergan units. Mixing those scales is one of the more dangerous conversion errors in practice, and the MHRA-approved Azzalure Summary of Product Characteristics<\/mark><\/a> states plainly that the units cannot be cross-converted.<\/p>\n\n\n\n

The mechanism is identical too. The toxin binds to presynaptic cholinergic nerve terminals, cleaves SNARE proteins, and blocks acetylcholine release at the neuromuscular junction. The treated muscle relaxes, dynamic lines soften, and movement gradually returns as the nerve terminal regenerates. What separates the two products is how they reach the syringe.<\/p>\n\n\n\n

Powder vs liquid: the same toxin, prepared differently<\/h2>\n\n\n\n
\n
\n
\"Azzalure<\/figure>\n<\/div>\n\n\n\n
\n

Azzalure arrives as a freeze-dried powder that you reconstitute with saline before use, so the concentration is set by the volume you add. Alluzience arrives as a ready-to-use liquid at a fixed 200 Speywood units per ml, with no mixing step.<\/p>\n\n\n\n

Same active molecule, same units, same glabellar dose \u2014 the difference is handling. The liquid format removes the dilution variable; the powder format gives you control over spread and a lower cost per vial.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Azzalure, the reconstitution workhorse<\/h2>\n\n\n\n

Azzalure is supplied as a lyophilised powder in a 125 Speywood unit vial. It holds a UK licence for two areas: moderate to severe glabellar lines seen at maximum frown, and lateral canthal lines (crow’s feet) seen at maximum smile, in adults under 65. That dual licence is part of why Azzalure remains a default upper-face toxin<\/mark><\/a> across the UK. The product is widely stocked, well understood, and has a long real-world safety record behind it.<\/p>\n\n\n\n

Getting the dilution right<\/h3>\n\n\n\n

Because Azzalure is a powder, it has to be reconstituted with 0.9% sodium chloride, and the volume chosen sets the concentration:<\/p>\n\n\n\n